Jonathan Pan, Ph.D, Mba Email & Phone Number

United States

Cambridge, Ma, Us

Brentford, Middlesex, Gb

 Leading an organization of 250+ people and >$120M+ turnover in Malaysia and Brunei, rebuilding the business in 2021 to exceed pre-pandemic 2019 levels with headcount expansion, new offices and achieving double digit growth in 2022 Led business units to deliver market share gains in all promoted General Medicines and secured top Market Share position for first time ever in majority of the brands promoted, delivering ~70% operating profit across the portfolio and growing almost 3x faster than market Built and delivered GSK First or Emerging Market First-time initiatives, such as buy now pay later schemes, ESG recycling programs for inhalers, and deployment of digital third party platforms for product promotion Won Pneumococcal Vaccine tender for Malaysian children under the age of 2 worth almost $35M and 3 million doses  Joined as a Board Member in the Pharmaceutical Association of Malaysia, British Malaysia Chamber of Commerce and co-chair of the Regulatory Affairs Committee, Chair of the BMCC Healthcare Committee and contributory partner in various policy position papers in the industry group for Malaysia and ASEAN Transformed the culture of the Malaysia Local Operating Company to be more agile and performance-oriented with single point of accountability with enhanced decision making, enabling decisions to be taken quicker and closer to the customer Delivered GSK separation from Haleon, operationalized distribution model in Brunei and activated therapy area focused business with ~15% increase in headcount, to deliver further growth

Brentford, Middlesex, Gb

 Led the formation of the medicine commercialization team, and enabling critical Commit to File and Launch decision with members of GSK Commercial Leadership Team (GCLT), enabling simultaneous approval and launch in the US and Europe in less than 2 years Set pricing strategy for BLENREP and developed framework to enable patient access while also preserving value for the medicine, leading to positive endorsement from CEO and corporate executive team Refined and delivered robust forecasting, commercial operations set-up, supply chain forecasting and launch campaign development to relevant stakeholders, including review with governance committees including CEO, CFO and GSKLT Engaged and partnered with research and development to develop and execute an ambitious development and commercialization plan, requiring fast, agile decision making and smart-risk taking across our top 5 markets Built a direct reporting, cross-geography team to enable all launch execution steps were enabled, to jump start market operations prior to launch, leading to continued alignment and executional prowess

Kuala Lumpur, Wilayah Persekutuan, My

Kuala Lumpur, Wilayah Persekutuan, My

Petaling Jaya, Selangor, My

Petaling Jaya, Selangor, My

 Led full development team including commercial, CMC, regulatory affairs, medical affairs, clinical operations and translation medicine for two development assets in immunology therapy areas Managed relationship with Kyowa Hakko Kirin for Anti-LIGHT program in Crohn’s Disease and second asset in another rare and orphan disease indication Initiated and organized Phase 1 program expansion from one clinical site to 5 sites, overcoming recruitment challenges in a highly competitive Crohn’s Disease area Conducted commercial due diligence on several assets (e.g., IL-18 from Large Top 10 BioPharma) for Oncology and Immunology related diseases, such as Leukemia, Lymphoma, and Macrophage Activation Syndrome Presented and led discussion with Board of Directors related to current development plans and commercial opportunities Developed Aevi’s clinical trial patient recruitment platform for clinical studies including social media, print and radio to drive trial awareness and to expedite clinical trial recruitment timelines

 Leading team of scientists and clinical operations staff in the development and execution of a comprehensive biomarker and companion diagnostic strategy from translational research, development, and regulatory through to commercialization Led regulatory Pre-Sub with FDA and met with Division Director, Deputy Director and Branch Chief, among others, to present data on a new diagnostic with follow-up minutes leading to a path for regulatory approval of the diagnostic Forged collaborations with various Children’s Hospitals and other research collaborators (e.g., Simons Foundation), and of note, leading the primary interface with Children’s Hospital of Philadelphia and the Center for Applied Genomics on developing new targets for drug development Evaluated different technologies (e.g., NGS, IHC, qPCR, Microarray) to determine best biomarker path on 4 different programs, leading to a framework for selected partners and platforms for use in our translational experiments

Lawrence Township, Nj, Us

 Leading cross-tumor, cross-geography commercial strategy development across 5 different priority markets and >30 tumor types, integrating into one cohesive go-to market strategy for Opdivo, Yervoy, Empliciti and other oncology assets Developed long-term risk mitigation strategy and developed tactical implementation to build strategic capabilities including infusion capacity expansion and new “white glove” patient services to increase differentiation Created presentations for senior management, board of directors, and investor community engaging with Investor Relations, Analytics and other key stakeholders to ensure a seamless description of our strategy Collaborating with Business Development and Early Commercial Strategy teams to identify new partnerships and acquisitions to strengthen long-term position of Immuno-Oncology Franchise

New Brunswick, Nj, Us

 Led and built the comprehensive commercial function including: new product strategy, global marketing, local marketing, business insights and overall commercial strategy with a team of 10 direct reports, managing a >$250MM P&L with >$25MM in brand marketing and G&A expenses; matrix leadership with regulatory, supply chain, sales and R&D Launched new Insulin Pump indication for pediatric patients, in the US the only insulin pump approved for children as young as 2 years of age (https://goo.gl/Y5ck6u) with a field of ~80 reps in the US Prepared and managed launch for new integrated insulin pumps and new closed-loop solutions for patients with Type 1 Diabetes, a major new innovation in diabetes management Collaborations with Business Development, R&D and other cross-functional leaders, leading efforts to define long-range technology and portfolio strategy on the journey toward the artificial pancreas

Basel, Baselstadt, Ch

Brentford, Middlesex, Gb

Reporting to the Global Head of Commercial at GSK Oncology and Medicine Commercialization Leader for Tafinlar and Mekinist, responsible for the commercial planning of companion diagnostics for pipeline products, go-to market strategy formulation and deployment for launched products (e.g., BRAF, MEK) and the formation of GSK’s enterprise diagnostic commercial strategy across therapeutic areas beyond oncology Pipeline Planning: Worked with R&D between GSK and another large Pharma to develop oncology screening strategy by leading the technical diligence and the commercial business model for a large program, leading to technology selection, strategy formation and risks/issues planning Go-to Market Strategy: Developed and led global strategy for 40+ countries to launch BRAF companion diagnostic and directly managed multiple market factors associated with test availability, turnaround time and diagnostic payment including developing a global testing network system, capable of generating patient and market value through a unique partnership with GE Healthcare Enterprise Strategy: Working to establish enterprise strategy across therapeutic areas and consolidating CDx complexity by incorporating basic planning frameworks and concepts into our pipeline planning and launch excellence program (e.g., TTP process) Corporate Strategy: Provided strategic input and part of core team for Corporate Executive Team strategic initiative to increase digital assets in multichannel marketing, eInhaler device analytics and digital clinical trials

Cambridge, Ma, Us

Cambridge, Ma, Us

Scientia Advisors is a global consulting firm focused on helping senior executives in the healthcare and life science industries select the right markets, choose attractive product opportunities, and streamline operations. Our clients range from Global 50 companies to emerging firms with cutting-edge technologies in healthcare, biotechnology, devices, diagnostics, therapeutics, and functional foods. We specialize in strategies for corporate, product and customer growth, mergers, acquisitions, alliances, financing, and valuation. Our approach is highly collaborative, disciplined, and success driven.

Danbury, Ct, Us

Served as a managing consultant on a long-standing, large oncology engagement, which has stemmed multiple follow-on projects Served as project manager for a global aesthetic market analysis project, liaising between 4 different global geographies, positioning our client to respond to market changes Managed and led development of market intelligence in the biologic therapy area, particularly in inflammation and vaccines products Spearheaded market due diligence in the UK healthcare market, benchmarking new commercial strategies through interviews with key opinion leaders, and identifying gaps between our client’s and other commercial models Served as lead consultant to create an advanced Excel-based market dynamics and future promotional spending forecast model to anticipate future market dynamics Collaborated on a cross-functional team to share business intelligence data, ultimately to close a 12 million dollar deal with a large international pharmaceutical company Developed capabilities pitch for bid team using our proprietary data analysis and gathering techniques for a large pharmaceutical company; resulting in additional follow-on work Therapy Area Specialties: Oncology, Biologics and Inflammation, Specialty Pharmaceuticals, and Biotech Over 40 Pharma/Biotech engagements with the top 13 of 20 companies in the industry

Worldwide, Oo

 Actively participated in major engagements focused on mitigating risk exposure and compliance for Federal clients Supported solution development in the healthcare segment to develop a logical database for electronic health records and partitioning data based upon use and need, while also remaining HIPAA compliant Developed and implemented project plans based upon client and Federal requirements, engaging C-level and senior management Developed assessment methodology to evaluate current state of a large Federal agency, leading to development of recommendations as part of an Agency’s strategic planning efforts Developed strategy with client to increase customer awareness and compliance with impending Federal deadline through active marketing strategies Identified operational inefficiencies, and proactively assisted in implementation of operational process improvement efforts that boosted overall efficiencies by 30 percent  Created strategic and tactical briefings for Chief of Physical Security and the Assistant Secretary  Served as on-site project manager, managing a team of consultants, and liaising with client on a daily basis Championed business development and networking efforts leading to increased client exposure to company service and product offerings

Ann Arbor, Michigan, Us

Ann Arbor, Michigan, Us

Bristow, Va, Us

 Actively participated on private equity engagements focused on the middle markets, detailing market dynamics, customer segments, and consumer/ competitive landscapes; playing a key role in reworking investment dynamics that totaled to approximately $200 million  Studied and identified market dynamics and trends of this particular market niche; utilized primary and secondary market data to create competitor landscape and modeled pricing patterns Performed customer analyses to identify needs, interests and vulnerabilities; conducted evaluations to determine positioning and growth strategies Designed and projected company demand- and supply-side growth for the next 10 years utilizing inputs from production data, marketing metrics, interviews from stakeholders within industry as well as research into upcoming state and federal legislation

Ph.D, Cellular And Molecular Biology

Master Of Science - Ms, Biology

B.Sc, Cellular And Molecular Biology

Finance And Operations

Mba, Business Administration - Strategy And Finance

Biology